Saudi Journal of Kidney Diseases and Transplantation

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 32  |  Issue : 6  |  Page : 1600--1614

Practice of Childhood Nephrotic Syndrome Management amongPediatric Nephrologists in the GCC Countries


Omar Alkandari1, Alanoud A. Alshami2, Entesar A. Alhammadi3 
1 Division of Pediatric Nephrology, Mubarak Al-Kabeer Hospital, Al-Jabriya, Kuwait; Division of Nephrology, Hamid Al-Essa Organ Transplant Center, Shuwaikh, Kuwait
2 Division of Pediatric Nephrology and Kidney Transplant, King Fahad Specialist Hospital, Dammam, Saudi Arabia, Kuwait
3 Division of Pediatric Nephrology, Dubai Hospital, Dubai, United Arab of Emirates

Correspondence Address:
Omar Alkandari
Division of Pediatric Nephrology, Mubarak Al-Kabeer Hospital, Al-Jabriya, Kuwait.
Kuwait

Childhood nephrotic syndrome (NS) management is greatly variable among pediatric nephrologists worldwide. We aimed to evaluate if this variability exists among pediatric nephrologists in the gulf countries and whether certain training programs influence this variability. A web-based multiple-choice survey of 35 NS management questions distributed to certified pediatric nephrologists working in the Gulf countries. Amongst 92 invitees, the response rate was 67%. The majority (73%) were older than 50 years and male (58%). Sixty percent trained in North America and 41% had >10 years of experience. Sixty-three percent use a 12- week corticosteroids regimen for the initial treatment of childhood NS and only 10% never consider long-term small alternate dose corticosteroids therapy to sustain remission before commencing a corticosteroids-sparing agent for frequently relapsing or corticosteroids-dependent NS. Mycophenolate mofetil was the drug of choice for frequently relapsing and corticosteroids dependent NS in 51% and 58% of the participants, respectively, whereas calcineurin inhibitors were preferred by the vast majority (95%) of the participants for corticosteroids-resistant childhood NS. Regarding rituximab treatment, almost half of the participants (48%) give two doses of rituximab one to two weeks apart and 61% do not give another course of rituximab until the child relapse. Fellowship training site and the duration of the clinical experience did not seem to influence certain management of childhood NS. As shown in North American studies, great variability in the management of childhood NS does exist in the Gulf countries. The country of fellowship training and the experience did not seem to contribute to this variability.


How to cite this article:
Alkandari O, Alshami AA, Alhammadi EA. Practice of Childhood Nephrotic Syndrome Management amongPediatric Nephrologists in the GCC Countries.Saudi J Kidney Dis Transpl 2021;32:1600-1614


How to cite this URL:
Alkandari O, Alshami AA, Alhammadi EA. Practice of Childhood Nephrotic Syndrome Management amongPediatric Nephrologists in the GCC Countries. Saudi J Kidney Dis Transpl [serial online] 2021 [cited 2022 Sep 27 ];32:1600-1614
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=2021;volume=32;issue=6;spage=1600;epage=1614;aulast=Alkandari;type=0